Physician profile
Crystal Gail Locklear
NPI 1750045498
$2,342.46
in general payments reported to CMS, 2019-2025
25 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.78 · 2022: $210 · 2023: $1,015 · 2024: $689 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.29 | 2023-2025 | |
| Novo Nordisk INC | $243.82 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.06 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $208.16 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $188.19 | 2022-2025 | |
| Ardelyx, INC. | $125.34 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $101.68 | 2023-2024 | Cologuard Collection Kit |
| Inari Medical, INC. | $77.89 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $75.97 | 2023-2024 | |
| Amgen INC. | $72.70 | 2022-2023 | Repatha, Otezla |
| Corcept Therapeutics | $71.15 | 2023-2025 | Korlym |
| Shield Therapeutics INC | $67.17 | 2024 | |
| Janssen Pharmaceuticals, INC | $63.77 | 2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.73 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $45.99 | 2022-2025 | Mounjaro, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.37 | 2025 | Voquezna |
| Medtronic, INC. | $38.27 | 2022-2025 | Venaseal |
| Dynavax Technologies Corporation | $34.51 | 2024 | Heplisav-B |
| Grifols USA, LLC | $21.27 | 2025 | Prolastin-C Liquid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.85 | 2023 | |
| Hologic Sales and Service, LLC | $16.35 | 2024 | Thinprep 2000 Processor, Aptima |
| Ironwood Pharmaceuticals, INC | $15.78 | 2022 | |
| Inspire Medical Systems, INC. | $14.97 | 2023 | Inspire |
| Recordati_rare_diseases_inc. | $14.70 | 2025 | Isturisa |
| Blueprint Medicines Corporation | $13.48 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.